In September 2002, eplerenone (Inspra; Pharmacia), the first selective aldosterone receptor antagonist, was approved by the FDA for the treatment of hypertension. Will it become as successful as established blockbuster drugs that also target the renin–angiotensin–aldosterone system?
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Mosterd, A. et al. Trends in the prevalence of hypertension, antihypertension therapy, and left ventricular hypertrophy from 1950 to 1999. N. Engl. J. Med. 340, 1221–1227 (1999).
Zaman, M. A., Oparil, S. & Calhoun, D. A. Drugs targeting the renin–angiotensin–aldosterone system. Nature Rev. Drug Discov. 1, 621–636 (2002).
McKelvie, R. et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study: The RESOLVD Pilot Study Investigators. Circulation 100, 1056–1064 (1999).
Rocha, R. & Funder, J. W. The pathophysiology of aldosterone in the cardiovascular system. Ann. NY Acad. Sci. 970, 89–100 (2002).
McMahon, E. G. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist. Curr. Opin. Pharmacol. 1, 190–196 (2001).
Brest, A. N. Spironolactone in the treatment of hypertension: a review. Clin.Ther. 8, 568–585 (1986).
Pitt, B. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709–717 (1999).
de Gasparo, M. et al. Three new spironolactone deriatives: characterization in vivo and in vitro. J. Pharmacol. Exp. Ther. 240, 650–656 (1987).
FDA Drug Approvals List [online] (cited 27 Jan 2003). http://www.fda.gov/cder/foi/label/2002/21437lbl.pdf
Quaschning, T. et al. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37, 801–805 (2001).
Sica, D. A. Current concepts of pharmacotherapy in hypertension. Eplerenone: a new aldosterone receptor antagonist — are the FDA restrictions appropriate? J. Clin. Hypertens. 4, 441–445 (2002).
Weinberger, M. et al. Comparison of eplerenone and losartan in patients with low-renin hypertension. Am. J. Hypertens. 15, A24 (2002).
Weber, M. Clinical implications of aldosterone blockade. Am. Heart J. 144, S12–S18 (2002).
Peter Kirkpatrick is Senior Editor of Nature Reviews Drug Discovery. Ruth Brown and Jeremy Quirk are Analysts
About this article
Aldosterone synthase inhibition: cardiorenal protection in animal disease models and translation of hormonal effects to human subjects
Journal of Translational Medicine (2014)
Current Hypertension Reports (2013)
Salt-sensitive hypertension in circadian clock–deficient Cry-null mice involves dysregulated adrenal Hsd3b6
Nature Medicine (2010)
Nature Reviews Drug Discovery (2003)